SIM0532 / Simcere - LARVOL DELTA

Simcere's pan-RAS inhibitor SIM0532 entering Phase I study (AllSci Corp) - "A newly posted Phase I trial record shows Simcere plans dose-expansion cohorts in pancreatic cancer, RAS-mutant non-small cell lung cancer (NSCLC) and other RAS-mutant solid tumors, placing the program in a mechanistic class now clinically validated by Revolution Medicines' daraxonrasib."

Trial status • Non Small Cell Lung Cancer • Pancreatic Cancer • Solid Tumor

A Phase I Study of SIM0532 in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=346 | Active, not recruiting | Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

First-in-human • New P1 trial • Oncology • Solid Tumor